Oncogenes y Dianas Efectoras
PANCCUN
Gustave Roussy Cancer Campus
Villejuif, FranciaPublicacións en colaboración con investigadores/as de Gustave Roussy Cancer Campus (2)
2024
-
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 2945-2953
2004
-
ERK 1/2 is activated in non-small-cell lung cancer and associated with advanced tumours
British Journal of Cancer, Vol. 90, Núm. 5, pp. 1047-1052